Drug Delivery Partnering Terms and Agreements in Pharma and Biotech, 2nd edition

The Drug Delivery Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 900 links to online copies of actual drug delivery contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of drug delivery dealmaking since 2000. The chapter includes numerous case studies to enable understanding of diagnostic dealmaking.

Chapter 3 provides an overview of the trends in drug delivery dealmaking since 2000.

Chapter 4 provides a review of the leading drug delivery deals since 2003. Deals are listed by headline value, signed by bigpharma, most active bigpharma, most active drug delivery companies, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the leading 35 drug delivery companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2000. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.